NewCardio has reported that three contract research organizations (CROs) have signed a Master Services Agreement (MSA), to use NewCardio’s Qtinno software suite as its technology in fully automated Thorough QT (TQT) and phase 1 studies delivered by its centralized ECG core lab.
NewCardio’s lead product is QTinno, a software suite that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators.
NewCardio expects to collaborate on the first fully automated study, tentatively scheduled to begin during the third quarter of 2009. It is anticipated that the customer will increasingly deliver fully automated results through QTinno in TQT/QT studies going forward.
Vincent Renz, president and chief operating officer at NewCardio, said: NewCardio is pleased to announce its second MSA, with a leading contract research organization, which represents another significant milestone in the industry adoption of QTinno, our automated cardiac safety solution.
Content from our partners
We look forward to working closely with them to rapidly implement our validated solution in order to meet their growing demand for fully automated trials. The agreement will enable them to deliver exactly what their customers are asking for: TQT/QT studies, which will minimize the risk of false positives or false negatives, all delivered in a more timely and more cost-effective manner than the current core lab methodologies allow, he added.
